Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by desl198on Oct 01, 2017 11:13am
69 Views
Post# 26763789

RE:RE:Concerns to consider

RE:RE:Concerns to consider
Agree with juansito. This is a risky penny play (as most of penny stocks are) However:

1 ICO has nothing to do with the price of Immune Pharma. In pas two years Immune went from 6$ to 1$, but ICo didn't move.
The reason you see their price moving together this time, it's because ico licensed to Immune the bertilimumab ,so,  Ico will receive royalties if trial is succesfull, as you can see from recent Immune news.
https://www.businesswire.com/news/h 2ome/20170804005457/en/Immune-Pharmaceuticals-Issues-Letter-Shareholders

2. Cash will last till h2 2018. Hopefully this will force Andrew Rae to either seek partership or to merge with Immune, in both cases it should be positive for ico. Andrew holds a chunk of ico shares and really concerned about dilution. He could have done a reverse split and dilution many times over in the past,  but didn't , (unike most of tsx Ventue companies.....) Inisder info:  https://apps.cnbc.com/view.asp?country=US&uid=stocks/ownership&symbol=ico-v&country=CA

3. A small bio company will never complete all phase 1 - 2-3 trials. You are correct. You should see this as a small mining exploration company, once something good is discovered, then company price shoots up or get bought out, in either case, sharrrholders are rewarded.

4. Nothing to do with tax season. Most people invested here are penny stock lovers, they don't have a classic portfolio that they "rebalance' for taxes. The aim is to win big or go home. As a proof, prrevious tax seasons the stock actually went up many times. look at the chart.

hope it answers your questions. I'm long the stock.

rrrrrrrrding to shareholderrrrrrr

<< Previous
Bullboard Posts
Next >>